Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)

June 25, 2026 3:33 AM

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $110.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found